Lymphoma Research Foundation Grants Nearly $4 Million to Boost Cancer Research Initiatives

Lymphoma Research Foundation Invests in Future of Cancer Research

In a significant move aimed at advancing the fight against lymphoma, the Lymphoma Research Foundation (LRF) has announced the allocation of nearly $4 million in research grants. These funds, amounting to exactly $3.9 million, will support 24 groundbreaking projects focused on improving the diagnosis and treatment of lymphoma, which remains one of the most prevalent types of blood cancer.

Founded as the largest nonprofit organization dedicated to funding innovative lymphoma research, the LRF plays a pivotal role in serving the lymphoma community. By offering education programs, outreach initiatives, and vital patient services, the Foundation strives to improve the lives of those affected by this challenging disease. The latest round of grants was announced on June 17, 2026, and marks another step in the Foundation's commitment to combating lymphoma.

The Scientific Advisory Board (SAB) of the Foundation, made up of esteemed leaders in lymphoma research, meticulously evaluated numerous grant applications to identify the most promising proposals. This year, the funding supports initiatives from 16 medical and academic institutions across North America, covering various subtypes of lymphoma and diverse scientific disciplines. Notable research areas include rare T-cell lymphomas, innovative treatments designed for adolescents and young adults, and novel cancer therapies aimed at understanding disease biology better.

Celebrating Rising Stars in Research

Andrew Evens, DO, MBA, MSc, and the Deputy Director for Clinical Services at Rutgers Cancer Institute, expressed enthusiasm about the new class of grantees. "This year's grant class represents the rising stars in lymphoma and chronic lymphocytic leukemia (CLL) research," said Evens. He emphasized the critical nature of the projects supported by the Foundation, stating, "These investigators are tackling some of the most urgent and important issues we face in the field of lymphoma today."

The grantee profile includes a diverse mix of talents:

- Clinical Career Development Awardees:

- Neha Akkad, M.D. (The University of Texas MD Anderson Cancer Center)
- Alexander Boardman, M.D. (Memorial Sloan Kettering Cancer Center)
- Mengyang Di, M.D., Ph.D. (University of Washington)

- Postdoctoral Fellowship Grant Recipients:

- Federico Mario Aletti, M.D. (The University of Texas MD Anderson Cancer Center)
- Thomas Corner, D.Phil. (Yale University)

- Mentoring Program Participants:

- Amaris Balitsky, M.D. (McMaster University)
- Yun Choi, M.D. (The Ohio State University)

These multifaceted research endeavors aim to drive progress by not only expanding our understanding of lymphoma's various subtypes but also in developing more effective treatment options for patients. As reflected by LRF’s commitment, the Foundation has dedicated over $85 million in research grants in the past 30 years, which have led to significant advancements in the field.

A Glimpse into the Future of Lymphoma Treatment

Meghan Gutierrez, the Chief Executive Officer of the Lymphoma Research Foundation, highlighted the importance of this investment in the future of lymphoma research. "With each grant, we take a step closer to unraveling the complexities of lymphoma and enhancing the treatment landscape for patients. We are honored to support these researchers, and it is through their dedication that we instill hope in patients and families grappling with lymphoma."

As news of the latest grants unfolds, the Foundation continues to set the stage for innovative cancer research. The Lymphoma Research Foundation invites the public to learn more about its initiatives and how it supports advances in lymphoma treatment by visiting lymphoma.org. Engage with the Foundation on social media platforms such as Facebook, Twitter, YouTube, Instagram, and LinkedIn for updates on progress and education.

The dedicated work by the LRF not only aims to empower researchers but fosters a community that strives for better healthcare outcomes for those affected by one of cancer’s most challenging forms. As research continues to push boundaries, the commitment remains firm: to tackle lymphoma head-on and offer hope where it is most needed.